...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: What Monday Brings?

Yes, all opinions matter. But if someone opens up a post by pondering "I have been sitting here wondering what if any good news we will hear" and offers no ideas, then this is either a sign of being uninformed or ignoring past Zenith communications. All I did was provide a summary of what I see as news items we could receive an update on, and provided clarification/reminders on what has been communicated to us regarding the re-organization and public listing. "Fussing?" "Sniping?" C'mon JK.

Share
New Message
Please login to post a reply